The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Posts about unexpected pregnancies while using drugs such as Ozempic for weight loss are trending on social media. Does any scientific evidence back this up? Sangeetha Nadarajah reports Amid the ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Credit: Novo Nordisk. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial. Semaglutide reduced the risk of kidney disease worsening, renal failure, and ...

Blockbuster obesity drugs such as Ozempic have been celebrated for their ability to promote weight loss and treat a surprising range of other conditions, from heart problems to Parkinson’s disease.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...